Long term incidence and the molecular basis of hepatitis B resistance to adefovir dipivoxil (ADV)

被引：0
|
作者：
Gibbs, CS
Qi, X
Yang, H
Delaney, WE
Das, K
Arnold, E
Thibault, V
Snow, A
Zhu, Y
Curtis, M
Hadziyannis, S
Westland, CE
Brosgart, CL
Arterburn, S
Miller, MD
Xiong, S
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Rutgers State Univ, CABM, Piscataway, NJ USA
[3] Hosp Pitie Salpetriere, Paris, France
[4] Henry Dunant Hosp, Athens, Greece
来源：
ANTIVIRAL RESEARCH | 2004年 / 62卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
9
引用
收藏
页码：A30 / A30
页数：1
相关论文
共 50 条
  • [21] Adefovir dipivoxil/lamivudineDevelopment of resistance in hepatitis B infection: case report
    Reactions Weekly, 2014, 1483 (1) : 7 - 7
  • [22] Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg- chronic hepatitis B (CHB) patients
    Hadziyannis, S
    Tassopoulos, N
    Chang, TT
    Heathcote, J
    Kitis, G
    Rizzetto, M
    Marcellin, P
    Lim, SG
    Arterburn, S
    Ma, J
    Xiong, S
    Brosgart, CL
    Currie, G
    JOURNAL OF HEPATOLOGY, 2005, 42 : 178 - 178
  • [23] Characterization of hepatitis B virus polymerase mutations detected during antiviral treatment with adefovir dipivoxil (ADV)
    Bock, Thomas
    Walker, Christine
    Koeberlein, Bernd
    Fischer, Conrad
    Kandolf, Reinhard
    Torresi, Joseph
    HEPATOLOGY, 2007, 46 (04) : 658A - 658A
  • [24] Combination of adefovir dipivoxil (ADV) and lamivudine (LAM) prevented emergence of ADV resistance mutations in chronic hepatitis B (CHB) patients with LAM-Resistant HBV
    Snow, A
    Thibault, V
    Qi, XP
    Zhu, Y
    Westland, C
    Arterburn, S
    Benhamou, Y
    Currie, G
    Brosgart, CL
    Miller, MD
    Xiong, S
    GASTROENTEROLOGY, 2005, 128 (04) : A745 - A745
  • [25] A NOVEL HEPATITIS B VIRUS MUTATION WITH RESISTANCE TO ADEFOVIR DIPIVOXIL IN PATIENTS WITH CHRONIC HEPATITIS B
    Liu, L. J.
    Wang, J. H.
    Du, S. C.
    Wei, L.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S334 - S335
  • [26] Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine
    Manalakopoulos, S.
    Bethanis, S.
    Koutsounas, S.
    Goulis, J.
    Vlachogiannakos, J.
    Christias, E.
    Savariadis, A.
    Pavlidis, C.
    Triantos, C.
    Christidou, A.
    Papatheodoridis, G.
    Karamanolis, D.
    Tzourmakliotis, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (03) : 266 - 273
  • [27] Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg- chronic hepatitis B (CHB) patients
    Hadziyannis, S
    Tassopoulos, N
    Chang, TT
    Heathcote, J
    Kitis, G
    Rizzetto, M
    Marcellin, P
    Lim, SG
    Arterburn, S
    Ma, J
    Xiong, S
    Brosgart, CL
    Currie, G
    GASTROENTEROLOGY, 2005, 128 (04) : A693 - A693
  • [28] THE HOST IMMUNITY RESPONSE OF HEPATITIS B PATIENTS AFTER ADEFOVIR DIPIVOXIL (ADV) AND ENTECAVIR (ETV) THERAPY
    Jiang, Y. -F.
    Gao, P. -J.
    Liu, J. -J.
    Xin, G. -J.
    Niu, J. -Q.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S210 - S211
  • [29] Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy
    Zoulim, F
    Trepo, C
    Poynard, T
    Pol, S
    Zarski, JP
    Marcellin, P
    Beaugrand, M
    Stitruk, V
    Trylesinski, A
    Kleber, K
    Van Doren, S
    Brosgart, C
    JOURNAL OF HEPATOLOGY, 2003, 38 : 184 - 184
  • [30] CHANGES IN CREATININE CLEARANCE (CRCL) IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH ADEFOVIR DIPIVOXIL (ADV)
    Ha, Nghi B.
    Ha, Nghiem B.
    Trinh, Huy N.
    Garcia, Ruel T.
    de Luna, Whitney
    Nguyen, Khanh K.
    Nguyen, Huy A.
    Levitt, Brian S.
    Nguyen, Mindie H.
    HEPATOLOGY, 2008, 48 (04) : 709A - 710A
12345